Skip to main content
Clinical Trials/NCT04741282
NCT04741282
Completed
N/A

Effect of Pulmonary Tele-rehabilitation With and Without Progressive Muscle Relaxation Program in Covid-19 Patients After Hospital Discharge: Randomized Clinical Trial

Iran University of Medical Sciences1 site in 1 country58 target enrollmentMay 1, 2021
ConditionsCovid19

Overview

Phase
N/A
Intervention
Not specified
Conditions
Covid19
Sponsor
Iran University of Medical Sciences
Enrollment
58
Locations
1
Primary Endpoint
Functional capacity
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The aim of this study is to investigate efficacy of internet based pulmonary rehabilitation and progressive muscle relaxation program on functional capacity, depression and anxiety, dyspnea, fatigue, sleep quality and quality of life in covid19 patients after hospital discharge

Detailed Description

Novel coronavirus disease 2019 (covid19) could cause respiratory and physical dysfunction, anxiety and depression, fatigue and affect sleep quality and quality of life in infected patient after hospital discharge. there is expect that pulmonary rehabilitation can improve these symptoms and prevent complications in these cases. It seems that Progressive muscle relaxation exercise could improve pulmonary rehabilitation effect. Due to social isolation of Covid 19 patients after hospital discharge, internet base rehabilitation will be used in this study. participants will be randomized in two pulmonary tele-rehabilitation groups after hospital discharge. One group will be received pulmonary rehabilitation include education, breathing exercises, aerobic and upper and lower limbs muscle strengthening exercises. Another group will be perform progressive muscle relaxation in addition of these exercise. Treatment duration is 6 week with 5 days/week frequency. Two exercise sessions per week will be supervised with expert physiotherapist via videoconferencing. Outcomes will be measured at baseline, within two week and at the end of six week exercises program.

Registry
clinicaltrials.gov
Start Date
May 1, 2021
End Date
October 30, 2021
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Covid 19 patient that confirmed with polymerase chain reaction test (PCR)
  • Hospitalized Corvid 19 patients after discharge
  • Accessibility to internet and using video call

Exclusion Criteria

  • Mental and physical disability
  • Uncontrolled cardiac dysfunction such as arrhythmia
  • Sever neurological condition such as guillain-barre and stroke
  • Uncontrolled diabetes or blood pressure
  • Pregnant women
  • Re-hospitalization during treatment program
  • Chronic pulmonary and kidney condition

Outcomes

Primary Outcomes

Functional capacity

Time Frame: change from baseline in 6MWT at 2 and 6 weeks

six minute walk test (6MWT)

Secondary Outcomes

  • Sleep quality(change from baseline in PSQI at 6 week)
  • dyspnea(change from baseline in Borg scale at 2 and 6 weeks)
  • anxiety and depression(change from baseline in HADS at 6 week)

Study Sites (1)

Loading locations...

Similar Trials